| [1] |
Miranda-Filho A, Lortet-Tieulent J, Bray F, et al.
Thyroid cancer incidence trends by histology in 25 countries: a population-based study[J]. Lancet Diabetes EndocrinolLancet Diabetes Endocrinol, 2021, 9(4): 225-234.
doi: 10.1016/s2213-8587(21)00027-9 |
| [2] |
Megwalu UC, Moon PK.
Thyroid cancer incidence and mortality trends in the United States: 2000-2018[J]. ThyroidThyroid, 2022, 32(5): 560-570.
doi: 10.1089/thy.2021.0662 |
| [3] |
中华医学会核医学分会.
131I治疗分化型甲状腺癌指南(2021版)[J]. 中华核医学与分子影像杂志中华核医学与分子影像杂志, 2021, 41(4): 218-241.
doi: 10.3760/cma.j.cn321828-20201113-00412 Chinese Society of Nuclear Medicine. Guidelines for radioiodine therapy of differentiated thyroid cancer (2021 edition)[J]. Chin J Nucl Med Mol ImagingChin J Nucl Med Mol Imaging, 2021, 41(4): 218-241. doi: 10.3760/cma.j.cn321828-20201113-00412 |
| [4] |
Berdelou A, Lamartina L, Klain M, et al.
Treatment of refractory thyroid cancer[J]. Endocr Relat CancerEndocr Relat Cancer, 2018, 25(4): R209-R223.
doi: 10.1530/erc-17-0542 |
| [5] |
Schlumberger M, Brose M, Elisei R, et al.
Definition and management of radioactive iodine-refractory differentiated thyroid cancer[J]. Lancet Diabetes EndocrinolLancet Diabetes Endocrinol, 2014, 2(5): 356-358.
doi: 10.1016/s2213-8587(13)70215-8 |
| [6] |
Wang FJ, Li ZF, Feng XQ, et al.
Advances in PSMA-targeted therapy for prostate cancer[J]. Prostate Cancer Prostatic DisProstate Cancer Prostatic Dis, 2022, 25(1): 11-26.
doi: 10.1038/s41391-021-00394-5 |
| [7] |
Verburg FA, Krohn T, Heinzel A, et al.
First evidence of PSMA expression in differentiated thyroid cancer using [68Ga]PSMA-HBED-CC PET/CT[J]. Eur J Nucl Med Mol ImagingEur J Nucl Med Mol Imaging, 2015, 42(10): 1622-1623.
doi: 10.1007/s00259-015-3065-y |
| [8] |
Verma P, Malhotra G, Agrawal R, et al.
Evidence of prostate-specific membrane antigen expression in metastatic differentiated thyroid cancer using 68Ga-PSMA-HBED-CC PET/CT[J]. Clin Nucl MedClin Nucl Med, 2018, 43(8): e265-e268.
doi: 10.1097/RLU.0000000000002161 |
| [9] |
Ciappuccini R, Saguet-Rysanek V, Giffard F, et al.
PSMA expression in differentiated thyroid cancer: association with radioiodine, 18FDG uptake, and patient outcome[J]. J Clin Endocrinol MetabJ Clin Endocrinol Metab, 2021, 106(12): 3536-3545.
doi: 10.1210/clinem/dgab563 |
| [10] |
Evans JC, Malhotra M, Cryan JF, et al.
The therapeutic and diagnostic potential of the prostate specific membrane antigen/glutamate carboxypeptidase Ⅱ (PSMA/GCPⅡ) in cancer and neurological disease[J]. Br J PharmacolBr J Pharmacol, 2016, 173(21): 3041-3079.
doi: 10.1111/bph.13576 |
| [11] |
Uijen MJM, Derks YHW, Merkx RIJ, et al.
PSMA radioligand therapy for solid tumors other than prostate cancer: background, opportunities, challenges, and first clinical reports[J]. Eur J Nucl Med Mol ImagingEur J Nucl Med Mol Imaging, 2021, 48(13): 4350-4368.
doi: 10.1007/s00259-021-05433-w |
| [12] |
Kuten J, Fahoum I, Savin Z, et al.
Head-to-head comparison of 68Ga-PSMA-11 with 18F-PSMA-1007 PET/CT in staging prostate cancer using histopathology and immunohistochemical analysis as a reference standard[J]. J Nucl MedJ Nucl Med, 2020, 61(4): 527-532.
doi: 10.2967/jnumed.119.234187 |
| [13] |
Taywade SK, Damle NA, Bal C.
PSMA expression in papillary thyroid carcinoma: opening a new horizon in management of thyroid cancer?[J]. Clin Nucl MedClin Nucl Med, 2016, 41(5): e263-e265.
doi: 10.1097/rlu.0000000000001148 |
| [14] |
Lengana T, Lawal IO, Mokoala K, et al.
68Ga-PSMA: a one-stop shop in radioactive iodine refractory thyroid cancer?[J]. Nucl Med Mol ImagingNucl Med Mol Imaging, 2019, 53(6): 442-445.
doi: 10.1007/s13139-019-00621-x |
| [15] |
Sasikumar A, Joy A, Pillai MRA, et al.
Rare case of intratracheal metastasis detected on 68Ga-prostate-specific membrane antigen PET/CT scan in a case of thyroglobulin elevated negative iodine scan syndrome[J]. Clin Nucl MedClin Nucl Med, 2018, 43(4): 282-283.
doi: 10.1097/rlu.0000000000001992 |
| [16] |
Hofman MS, Violet J, Hicks RJ, et al.
[177Lu]-PSMA-617 radionuclide treatment in patients with metastatic castration-resistant prostate cancer (LuPSMA trial): a single-centre, single-arm, phase 2 study[J]. Lancet OncolLancet Oncol, 2018, 19(6): 825-833.
doi: 10.1016/s1470-2045(18)30198-0 |
| [17] |
de Vries LH, Lodewijk L, Braat AJAT, et al. 68Ga-PSMA PET/CT in radioactive iodine-refractory differentiated thyroid cancer and first treatment results with 177Lu-PSMA-617[J/OL]. EJNMMI Res, 2020, 10(1): 18[2023-06-24]. https://ejnmmires.springeropen.com/articles/10.1186/s13550-020-0610-x. DOI: 10.1186/s13550-020-0610-x. |
| [18] |
Assadi M, Ahmadzadehfar H.
177Lu-DOTATATE and 177Lu-prostate-specific membrane antigen therapy in a patient with advanced metastatic radioiodine-refractory differentiated thyroid cancer after failure of tyrosine kinase inhibitors treatment[J]. World J Nucl MedWorld J Nucl Med, 2019, 18(4): 406-408.
doi: 10.4103/wjnm.WJNM_112_18 |